After a slow 2024, the biotech shell company Concentra Biosciences is back, offering to buy four biotechs in the past month ...

Discover why some biotechs fail but survive with cash on hand, and how players like Concentra are trying to unlock trapped ...

Concentra has a reputation for picking up biotechs that are down on their luck, and iTeos certainly fits the bill. The company’s main focus up until May was the anti-TIGIT antibody belrestotug ...

The company said it couldn't provide estimates for contract and lease termination costs, or the costs to shutter the belrestotug program. The wind down is expected to be substantially completed in ...

GSK and iTeos are the latest companies to scrap a jointly developed anti-TIGIT drug after it failed to demonstrate a meaningful benefit in two Phase II trials. Belrestotug, a human IgG1 antibody ...

– GALAXIES Lung-201 did not meet established criteria for clinically meaningful improvements in progression free survival– Based on totality of data, iTeos and GSK have agreed to terminate the ...

All belrestotug-containing cohorts are ending, and any new enrollment in the ongoing GALAXIES Lung-301 Phase 3 trial is ending. GSK is communicating with investigators, institutional review boards, ...

Based on these results, iTeos and GSK have made the decision to terminate the belrestotug development program and end the collaboration. All belrestotug-containing cohorts are ending, and any new ...

About Belrestotug (EOS-448/GSK4428859A) Belrestotug is an Fc active human immunoglobulin G1, or IgG1, monoclonal antibody (mAb) targeting T cell immunoglobulin and immunoreceptor tyrosine-based ...

It said the collaboration and all belrestotug-containing study cohorts are ending as a result. The drug was being developed as a potential treatment for various cancers.